The Molecular Hepatology Group investigates the cellular and molecular causes underlying the development of different liver pathologies. It is a consolidated group at IMIBIC composed of a multidisciplinary team of postdoctoral and predoctoral researchers with experience in different areas of Biomedicine.
The research of the Molecular Hepatology Group focuses on the study of the deregulation of gene expression control mechanisms, RNA biogenesis, mRNA metabolism (splicing, NMD, RNA-exosome, etc.) and protein synthesis and maturation in the development and progression of different liver pathologies such as fatty liver disease, cirrhosis or liver cancer. We also study the involvement of metabolic dysregulation (obesity, diabetes, metabolic syndrome) and, therefore, the associated cellular, molecular and endocrine systems (somatostatin, ghrelin, adipokines, hepatokines, etc.) in these liver pathologies. To this end, we use different genetic and cellular and molecular biology approaches, as well as cell culture techniques, preclinical animal models and clinical samples obtained through collaboration with different groups at IMIBIC and other centres.
The ultimate goal of this research is to identify new molecular targets that can be used to improve the diagnosis of patients with liver diseases, to estimate their prognosis more accurately or to help develop new therapeutic approaches for their treatment. To this end, we have received continuous public and private funding over the last few years, which has resulted in the publication of several research articles and the establishment of patents that protect the possible clinical application of this research.
Lines of Research
Characterisation of cellular and molecular mechanisms underlying the development and progression of liver diseases.
Identification of new biomarkers for the diagnosis and/or prognosis of liver diseases.
Study of the molecular principles involved in the relationship between metabolic dysregulation and liver pathologies.
Búsqueda de nuevas dianas terapéuticas para el tratamiento de enfermedades hepáticas
Networks
CIBERobn - Centro de Investigación Biomédica en Red - Fisiopatología de la Obesidad y Nutrición
Red de Investigación Nacional (RED2018-102785-E) - Ministerio de Ciencia, Innovación y Universidades
PAIDI BIO-139 - Endocrinología Celular y Molecular.
SEEN - Sociedad Española de Endocrinología y Nutrición (Grupo de Trabajo de Enfermedad Hepática Metabólica)
ESE - Sociedad Europea de Endocrinología. Focus Area: Tumores endocrinos
Key Words
- Hígado graso
- NAFLD
- MAFLD
- cirrosis
- NASH
- cáncer de hígado
- hepatocarcinoma
- colangiocarcinoma
- obesidad
- diabetes
- síndrome metabólico
- ARN
- splicing
- spliceosoma
- non-sense mediated decay
- NMD
- ARN-exosoma
- ARNt
- biogénesis del ARN
- síntesis de proteínas
- sistemas endocrinos
- somatostatina
- ghrelina
- GH
- IGF
- hepatoquinas
- adipoquinas
- modelos preclínicos.
Información Adicional
Patents
Non-invasive diagnostic method for cancer. Luque RM, Castaño JP, Gahete MD, Ibáñez-Costa A, Hormaechea-Agulla D, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201631606 - PCT/ES2017/070797
Peptides derived from the truncated somatostatin receptor sst5TMD4 as biomarkers and therapeutic targets in tumor pathologies. Luque RM, Castaño JP, Gahete MD, del Río-Moreno M, Alors-Pérez E. P201730702 - PCT/ES2018/070361
Method for the prediction and prognostic of the development of type 2 diabetes mellitus. Luque RM, Gahete MD, López-Miranda J, Perez-Martínez P, Delgado-Lista J, García-Ríos A, Alcalá-Díaz JF, Yubero-Serrano E, Camargo-García A, del Río-Moreno M, Alors-Pérez E, Castaño JP, Ventura-Soto S, Reyes-Pupo O. P201831095
Method for the diagnosis, prognosis and treatment of neuroendocrine tumors. Luque RM, Castaño JP, Gahete MD, Pedraza-Arévalo S, del Río-Moreno M, Alors-Pérez E, Gálvez-Moreno MA, Herrera-Martínez A, Serrano-Blanch R. P201831039
Method for the diagnosis and prognosis of the development of prostate cancer. Luque RM, Gahete MD, Castaño JP, Jiménez-Vacas JM, Sarmento-Cabral A, L-López F, Requena-Tapia MJ, Gómez-Gómez E, Carrasco-Valiente J. P201930104
Method for the diagnosis and prognosis of the development of brain tumors. Luque RM, Gahete MD, Fuentes-Fayos AC, Castaño JP, Ibañez-Costa A, Vazquez-Borrego MC, Lopez-Lopez F, Blanco-Acebedo C, Solivera-Vela J, Toledano-Delgado A, Galvez-Moreno MA. P201931147
Compounds for the treatment of hepatocelular carcinoma. Gahete MD, López-Cánovas JL, Luque RM, Castaño JP, del Rio-Moreno M, de la Mata M, Rodríguez-Prealvarez M, Sánchez-Frías ME. P202030723
